Schrödinger (SDGR) Competitors $19.44 +0.14 (+0.73%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SDGR vs. LEGN, NUVL, IONS, BPMC, ELAN, CYTK, CORT, TGTX, VKTX, and TLXShould you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Legend Biotech (LEGN), Nuvalent (NUVL), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Corcept Therapeutics (CORT), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical preparations" industry. Schrödinger vs. Legend Biotech Nuvalent Ionis Pharmaceuticals Blueprint Medicines Elanco Animal Health Cytokinetics Corcept Therapeutics TG Therapeutics Viking Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Legend Biotech (NASDAQ:LEGN) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations. Does the media refer more to LEGN or SDGR? In the previous week, Legend Biotech had 4 more articles in the media than Schrödinger. MarketBeat recorded 7 mentions for Legend Biotech and 3 mentions for Schrödinger. Schrödinger's average media sentiment score of 1.49 beat Legend Biotech's score of 0.49 indicating that Schrödinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Schrödinger 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in LEGN or SDGR? 70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 79.1% of Schrödinger shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 8.6% of Schrödinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate LEGN or SDGR? Legend Biotech currently has a consensus price target of $81.54, indicating a potential upside of 139.26%. Schrödinger has a consensus price target of $32.90, indicating a potential upside of 69.24%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Schrödinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Schrödinger 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Does the MarketBeat Community believe in LEGN or SDGR? Legend Biotech received 30 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 71.55% of users gave Legend Biotech an outperform vote while only 56.99% of users gave Schrödinger an outperform vote. CompanyUnderperformOutperformLegend BiotechOutperform Votes8371.55% Underperform Votes3328.45% SchrödingerOutperform Votes5356.99% Underperform Votes4043.01% Is LEGN or SDGR more profitable? Legend Biotech has a net margin of -66.92% compared to Schrödinger's net margin of -91.84%. Legend Biotech's return on equity of -29.69% beat Schrödinger's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-66.92% -29.69% -19.45% Schrödinger -91.84%-35.77%-24.51% Which has preferable valuation and earnings, LEGN or SDGR? Schrödinger has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$520.18M11.97-$518.25M-$0.95-35.87Schrödinger$193.35M7.33$40.72M-$2.34-8.31 Which has more risk and volatility, LEGN or SDGR? Legend Biotech has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. SummaryLegend Biotech beats Schrödinger on 12 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Schrödinger News Delivered to You Automatically Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SDGR vs. The Competition Export to ExcelMetricSchrödingerPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-8.3110.5991.3417.19Price / Sales7.33195.381,116.59116.80Price / Cash32.4857.1642.6437.86Price / Book2.565.104.794.78Net Income$40.72M$151.51M$120.07M$225.60M7 Day Performance-6.67%-2.15%-1.89%-1.24%1 Month Performance-4.65%-3.14%11.45%3.36%1 Year Performance-44.12%11.50%30.61%16.58% Schrödinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SDGRSchrödinger2.3678 of 5 stars$19.44+0.7%$32.90+69.2%-42.3%$1.41B$193.35M-8.31867Positive NewsLEGNLegend Biotech1.5523 of 5 stars$33.83-3.7%$81.54+141.0%-43.2%$6.18B$520.18M-36.971,800NUVLNuvalent2.1944 of 5 stars$86.65-0.2%$112.60+29.9%+16.9%$6.16BN/A-25.0340Insider TradeNews CoveragePositive NewsIONSIonis Pharmaceuticals4.4164 of 5 stars$38.46+5.1%$60.65+57.7%-26.3%$6.07B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageBPMCBlueprint Medicines2.5701 of 5 stars$95.39+2.4%$122.11+28.0%+7.2%$6.06B$249.38M-44.17640Insider TradeELANElanco Animal Health3.7792 of 5 stars$12.09-0.1%$16.75+38.5%-17.0%$5.98B$4.45B30.259,300CYTKCytokinetics4.1408 of 5 stars$49.17+1.1%$83.93+70.7%+36.8%$5.80B$3.22M-9.04250Analyst ForecastCORTCorcept Therapeutics4.9122 of 5 stars$55.13-0.5%$65.25+18.4%+66.5%$5.78B$482.38M43.97300Analyst RevisionTGTXTG Therapeutics4.3127 of 5 stars$34.78+8.6%$40.67+16.9%+87.1%$5.41B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2931 of 5 stars$48.07+2.2%$106.75+122.1%+139.8%$5.36BN/A-51.5620Analyst ForecastGap UpTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$15.76+1.0%$21.00+33.2%N/A$5.28BN/A0.00N/ANews CoverageGap Down Related Companies and Tools Related Companies LEGN Competitors NUVL Competitors IONS Competitors BPMC Competitors ELAN Competitors CYTK Competitors CORT Competitors TGTX Competitors VKTX Competitors TLX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SDGR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrödinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrödinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
